BLACKSBURG, VIRGINIA, May 23, 2018– Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that the company would be participating in Digestive Disease Week and the Bio International Convention in June.
“We are pleased to have the opportunity to present our company and science at these two prestigious conferences at a time when BT-11 is entering the clinical development stage,” said Dr. Bassaganya-Riera. “Our lead compound BT-11 is a first-in-class oral therapeutic for Crohn’s disease and ulcerative colitis that has the potential to disrupt the treatment paradigm. We expect to file two INDs and initiate a Phase 1 clinical trial in the coming months.”
- At Digestive Disease Week, Andrew Leber, PhD, Scientific Director at Landos Biopharma, will present findings on the mechanisms of action for its lead candidate in a poster (Abstract: Tu1739) titled Translation of Immunometabolic Mechanisms of BT-11 to Humans with Crohn’s Disease on June 5th from 12:00 – 2:00 pm.
- At Digestive Disease Week, Landos will also convene a meeting of its Clinical Advisory Board (CAB) to discuss its Phase 2 clinical program in Crohn’s disease and ulcerative colitis on June 3rd . Landos’ CAB is composed of key opinion leaders in Crohn’s and colitis: Drs. William Sandborn, Jean-Frederic Colombel, Fabio Cominelli, Francisco Sylvester and Maria Abreu.
- At the Bio International Convention in Boston, MA, Dr. Josep Bassaganya-Riera, Chairman and CEO, will participate on the “Translating Immunological Insights from Oncology to Other Disease Areas” panel on June 5th from 1:45 – 2:45 pm.
- Also, at the Bio International Convention, Dr. Bassaganya-Riera will present a corporate and clinical program update on June 5th from 4:15 pm – 4:30 pm.
Landos’ lead product candidate BT-11 is a first-in-class, orally active therapeutic that acts locally in the gastrointestinal tract for treatment of Crohn’s disease and ulcerative colitis. BT-11 has shown outstanding therapeutic efficacy in preclinical models, a benign safety profile without the concerns of systemic exposure, and it is advancing toward two Investigational New Drug (IND) filings in 2018. BT-11 intercepts IBD by decreasing the production of inflammatory mediators and increasing anti-inflammatory molecules within the gastrointestinal tract.
About Landos Biopharma, Inc.
Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD) and is expected to enter clinical testing for Crohn’s disease and ulcerative colitis in 2018. Landos also has a robust pipeline of compounds for other autoimmune diseases. Landos is headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com or contact firstname.lastname@example.org or follow us @Landosbio.
For Media Requests: